The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Tumor drug distribution and target engagement of MLN9708, an investigational proteasome inhibitor, in patients with advanced solid tumors.
Alessandra Di Bacco
Employment or Leadership Position - Millennium; Millennium
Allison Berger
Employment or Leadership Position - Millennium
Neeraj Gupta
Employment or Leadership Position - Millennium
Stock Ownership - Millennium
Feng Gao
Employment or Leadership Position - Millennium
Stephen Blakemore
Employment or Leadership Position - Millennium
Mark Qian
Employment or Leadership Position - Millennium
Susan Chen
Employment or Leadership Position - Millennium
Bradley Stringer
Employment or Leadership Position - Millennium
Yu Yang
Employment or Leadership Position - Millennium
Ray Liu
Employment or Leadership Position - Millennium
Stephen Tirrell
Employment or Leadership Position - Millennium
Doug Bowman
Employment or Leadership Position - Millennium
David C. Smith
Research Funding - Millennium
Daniel Sullivan
No relevant relationships to disclose
Jeffrey R. Infante
No relevant relationships to disclose
John S. Kauh
No relevant relationships to disclose
Lillian L. Siu
Research Funding - Millennium
Gordana Vlahovic
Consultant or Advisory Role - Genentech
John A. Thompson
Research Funding - Millennium
Thea Kalebic
Employment or Leadership Position - Millennium